PMID- 37403008
OWN - NLM
STAT- MEDLINE
DCOM- 20230905
LR  - 20230913
IS  - 1534-6277 (Electronic)
IS  - 1534-6277 (Linking)
VI  - 24
IP  - 9
DP  - 2023 Sep
TI  - Targeting HIF-2 Alpha in Renal Cell Carcinoma.
PG  - 1183-1198
LID - 10.1007/s11864-023-01106-y [doi]
AB  - Current treatment options for patients with metastatic renal cell carcinoma 
      (mRCC) are limited to immunotherapy with checkpoint inhibitors and targeted 
      therapies that inhibit the vascular endothelial growth factor receptors (VEFG-R) 
      and the mammalian target of rapamycin (mTOR). Despite significantly improved 
      outcomes over the last few decades, most patients with mRCC will ultimately 
      develop resistance to these therapies, thus highlighting the critical need for 
      novel treatment options. As part of the VHL-HIF-VEGF axis that rests at the 
      foundation of RCC pathogenesis, hypoxia-inducible factor 2alpha (HIF-2alpha) has been 
      identified as a rationale target for mRCC treatment. Indeed, one such agent 
      (belzutifan) is already approved for VHL-associated RCC and other VHL-associated 
      neoplasms. Early trials of belzutifan indicate encouraging efficacy and good 
      tolerability in sporadic mRCC as well. The potential inclusion of belzutifan and 
      other HIF-2alpha inhibitors into the mRCC treatment armamentarium either as a single 
      agent or as combination therapy would be a welcome addition for patients with 
      mRCC.
CI  - (c) 2023. The Author(s), under exclusive licence to Springer Science+Business 
      Media, LLC, part of Springer Nature.
FAU - Ahmed, Ramsha
AU  - Ahmed R
AD  - Division of Hematology and Oncology, Department of Medicine, Medical College of 
      Wisconsin, 9200 W. Wisconsin Ave., Milwaukee, WI, 53226, USA.
FAU - Ornstein, Moshe C
AU  - Ornstein MC
AUID- ORCID: 0000-0003-0184-3467
AD  - Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer 
      Institute, 9500 Euclid Ave, CA-60, Cleveland, OH, 44195, USA. ornstem@ccf.org.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230705
PL  - United States
TA  - Curr Treat Options Oncol
JT  - Current treatment options in oncology
JID - 100900946
RN  - 1B37H0967P (endothelial PAS domain-containing protein 1)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 7K28NB895L (belzutifan)
RN  - 0 (Basic Helix-Loop-Helix Transcription Factors)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Renal Cell/drug therapy/etiology/metabolism
MH  - *Kidney Neoplasms/drug therapy/etiology/metabolism
MH  - Vascular Endothelial Growth Factor A
MH  - Basic Helix-Loop-Helix Transcription Factors
OTO - NOTNLM
OT  - Belzutifan
OT  - HIF-2alpha
OT  - Kidney cancer
OT  - MK-6482
OT  - Renal cell carcinoma
OT  - VHL
EDAT- 2023/07/05 01:06
MHDA- 2023/09/05 06:42
CRDT- 2023/07/04 23:34
PHST- 2023/05/12 00:00 [accepted]
PHST- 2023/09/05 06:42 [medline]
PHST- 2023/07/05 01:06 [pubmed]
PHST- 2023/07/04 23:34 [entrez]
AID - 10.1007/s11864-023-01106-y [pii]
AID - 10.1007/s11864-023-01106-y [doi]
PST - ppublish
SO  - Curr Treat Options Oncol. 2023 Sep;24(9):1183-1198. doi: 
      10.1007/s11864-023-01106-y. Epub 2023 Jul 5.